文献速递肝肾功能剂量调整特殊人群用药

机制性PBPK-PD模型预测siRNA疗法临床药代/药效及器官损伤影响

Predicting Clinical Pharmacokinetics/Pharmacodynamics and Impact of Organ Impairment on siRNA-Based Therapeutics Using a Mechanistic Physiologically-Based Pharmacokinetic-Pharmacodynamic Model.
PubMed 文献 · Clin Pharmacol Ther · 2024-01-28

该研究构建了机制性生理药代-药效(PBPK-PD)模型,以inclisiran和vutrisiran为案例,评估肝/肾功能损伤对GalNAc-siRNA药代/药效的影响。模型预测肝ASGPR浓度降低30-70%仍可产生与正常肝功能相当程度和持续时间的药效,肾功能变化对PD影响极小。

要点

  • 肝ASGPR降至正常的30-70%时,游离胞质siRNA仍足以加载RISC并产生与正常肝功能相当程度和持续时间的药效。
  • 肾功能生理变化(包括不同损伤程度的GFR改变)预测对inclisiran和vutrisiran的PD影响极小。
  • 该机制性PBPK-PD框架可支持siRNA疗法的临床转化和给药考虑。

核心结论

  • 机制性PBPK-PD模型可定量评估器官损伤对siRNA药代/药效的影响,并支持临床转化与给药考虑。

研究设计与样本

  • 基于生理的药代-药效(PBPK-PD)建模框架,以FDA批准的inclisiran和vutrisiran为案例研究,利用可得组织特异性数据并转化至人类。

主要发现

  • 肝ASGPR浓度降低30-70%仍允许足够量游离胞质siRNA加载RISC,产生与正常肝功能相当程度和持续时间的药效,包括无临床数据的严重肝损伤。
  • 纳入其他与器官损伤相关的模态无关生理变化未改变上述发现。
  • 肾功能生理变化(包括不同损伤程度的GFR改变)良好预测inclisiran和vutrisiran的PD变化极小。

关键数值与推荐

  • 肝ASGPR浓度降低30-70%时,药效在程度和持续时间上与正常肝功能相当。

临床怎么用

  • 可利用该机制性PBPK-PD框架评估器官损伤对GalNAc-siRNA药代/药效的影响,指导给药考虑和临床转化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Approved and emerging siRNA therapeutics are primarily designed for targeted delivery to liver where the therapeutic gene silencing effects occurs. Impairment of hepatic/renal function and its impact on siRNA pharmacokinetics/pharmacodynamics (PKs/PDs) are yet to be mechanistically evaluated to describe the unanticipated clinical observations for this novel modality. We developed pathophysiologically relevant models for organ impairment within a physiologically-based PK-PD (PBPK-PD) modeling framework focusing on modality-specific mechanistic factors to evaluate impact on siRNA PKs and PDs. PBPK-PD models for two US Food and Drug Administration (FDA) approved siRNAs inclisiran and vutrisiran were developed as case studies leveraging available tissue-specific data and translated to humans. Key determinants of the clinical PK and PD of N-acetylgalactosamine conjugated siRNAs (GalNAc-siRNAs) with varying sequences were also identified to inform effective clinical translation strategies for emerging GalNAc-siRNA candidates. A 30-70% reduction in hepatic asialoglycoprotein receptors concentrations still allowed for sufficient amount of free cytoplasmic siRNA for RISC-loading to produce PD effects comparable in extent and duration to normal liver function. This included severe hepatic impairment for which no clinical data are available. Inclusion of other modality agnostic physiological changes relevant to organ impairment did not alter the findings. Changes in renal physiologies, including changes in GFR across various degrees of impairment, well predicted minimal changes in PD for inclisiran and vutrisiran. This work provides a quantitative mechanistic framework and insights on modality-specific factors that drive clinical translation and patient/disease-related factors that impact specific dosing considerations and clinical outcomes to help accelerate the optimal development of siRNA therapeutics.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lumen A, Zhang X, Dutta S, et al. Predicting Clinical Pharmacokinetics/Pharmacodynamics and Impact of Organ Impairment on siRNA-Based Therapeutics Using a Mechanistic Physiologically-Based Pharmacokinetic-Pharmacodynamic Model. Clin Pharmacol Ther. 2024. PMID: 38282246. doi:10.1002/cpt.3160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。